PB 130 of 2023
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 12)
National Health Act 1953
___________________________________________________________________________
I, NIKOLAI TSYGANOV, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make this Instrument under subsection 98C(1) of the National Health Act 1953.
Dated 21 December 2023
NIKOLAI TSYGANOV
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Contents
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019
(1) This instrument is the National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Amendment Determination 2023 (No. 12).
(2) This instrument may also be cited as PB 130 of 2023.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. The whole of this instrument | 1 January 2024 | 1 January 2024 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
3 Authority
This instrument is made under subsection 98C(1) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
Schedule 1—Amendments
National Health (Commonwealth Price and Conditions for Commonwealth Payments for Supply of Pharmaceutical Benefits) Determination 2019 (PB 114 of 2019)
[1] Schedule 3, after entry for Hydromorphone in the form Oral solution containing hydromorphone hydrochloride 1 mg per mL, 1 mL
insert:
Hydromorphone | Oral solution containing hydromorphone hydrochloride 1mg per mL, 1mL (S19A) |
[2] Schedule 4, after entry for Levetiracetam
insert:
Lumacaftor with ivacaftor | Sachet containing granules, lumacaftor 75 mg and ivacaftor 94 mg |